The Study
We are studying a novel drug called Trametinib, an FDA-approved drug for the treatment of people with melanoma, for the treatment of cancer in dogs. Previous research showed trametinib to be highly effective against canine histiocytic sarcoma. Differently from conventional chemotherapies, trametinib blocks specific factors that cancer cells use to continue multiplying and surviving. The goal of this study is to evaluate the effects of this drug on the tumor and its safety profile in dogs with cancer.

Who Qualifies
Dogs with any type of cancer that are not currently receiving chemotherapy.

What Happens
Dogs will receive trametinib orally once a day on an outpatient basis. Sample collections will be performed during the first week of treatment. Patients will then be evaluated every 3 weeks after the start of treatment. Owners will be asked to complete questionnaires throughout the duration of the study.

Why Participate
The study will allow us to evaluate the effect and tolerability of trametinib in dogs with cancer. The ultimate goal of this study is to define the role of trametinib as a novel targeted therapy for dogs with histiocytic sarcoma, improving their outcome and survival. Dogs with other types of cancer will likely benefit from trametinib as well. The drug itself, as well as recheck physical exams and blood work will be paid for by the study.

More Information
Please contact Marilia Takada, DVM, MS, PhD at takada@wisc.edu; David Vail, DVM, DACVIM (Onc) at david.vail@wisc.edu; or Amanda Brooks, CVT at simons5@wisc.edu for more information.